TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ESES and clinical CSWS/LKS defined by all of the following:~* SWI ≥50% during first hour of sleep~* Bilateral synchrony of discharges during sleep~* Clinical evidence of behavior and/or academic regression~* Daytime SWI ≤20%~Exclusion Criteria:~* Previous treatment with benzodiazepine or acetazolamide for Electrical Status Epilepticus in Sleep (ESES)~* Current treatment with carbamazepine, phenytoin, oxcarbazepine, phenobarbital, vigabatrin or lamotrigine~* Antiepileptic medication changes over the month prior to enrollment~* Epileptic encephalopathy other than CSWS/LKS~* Prior serious adverse reaction to benzodiazepines or acetazolamide~* Sulfa allergy~* Progressive underlying neurologic condition~* Frequent seizures that would prevent the patient from maintaining a stable dose of medications~* Female patient that has begun menses or is pregnant

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Diazepam (Type: ACTIVE_COMPARATOR): Diazepam 0.5 mg/kg (up to maximum 20 mg) by mouth nightly. Duration of therapy is 4 weeks.
- Acetazolamide (Type: EXPERIMENTAL): Acetazolamide 8-10 mg/kg (up to a maximum dose of 375 mg) by mouth (PO)divided twice daily X 1 week, then increased to 11-16 mg/kg (up to a maximum dose of 750 mg) by mouth divided twice daily thereafter. Duration of therapy is 4-8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Estrogen Patch for COVID-19 Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male ≥ 18 years of age or female ≥ 55 years of age~* Documentation of COVID19 positivity or the presence of one or more of the following new onset (\<7 days) clinical features defining presumptive COVID19~  1. fever of \>100.5°F or 38°C~ 2. shortness of breath~ 3. cough~ 4. radiologic evidence of pneumonia~* Able to provide informed consent~* Able to be contacted by telephone for follow-up~Exclusion Criteria:~* Currently receiving estrogen based hormonal therapy~* Abnormal genital bleeding~* Protein C or Protein S deficiency~* Pre-existing liver impairment (e.g. Hepatitis C, cirrhosis)~* History of anaphylactic reaction or angioedema with Climara~* Receiving lamotrigine therapy~* Subjects with known past diagnosis of estrogen receptor positive breast cancer or endometrial cancer~* Subjects with severe hypoxia at risk for acute intubation in ED~* History of stroke~* Any history of thromboembolic event including deep vein thrombosis or pulmonary emboli~* Current use of St. John's Wort~* Males on testosterone~* History of myocardial infarction, cardiac stents, or active angina

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Estradiol Patch
- Control (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Value on Survival of Liver Volume After an Acute Decompensation of an Alcoholic Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients~* Patient suffering from alcoholic cirrhosis (withdrawn or not)~* Patient admitted in emergency for an alcoholic cirrhosis decompensation only~* Prescription for a cutting imaging (CT scan or MRI) during hospitalisation~* Alcohol consumption of more than 3 units per day for men and 2 units for women in average, over at least the last 5 years before the cirrhosis diagnosis~* Patient suffering from decompensated cirrhosis defined by at least one of the following criteria : Model For End-Stage Liver Disease (MELD) score above or equal to 15, ascites needing iterative punctures, symptomatic bacterial ou fungal infections, acute digestive bleeding due to portal hypertension, hepatic encephalopathy defined by a West Haven score above or equal to 2~Exclusion Criteria:~* Nodule with typical criteria of hepatocellular carcinoma~* B or C viral infections actives~* Presence of transjugular intrahepatic portosystemic shunt (TIPS)~* Presence of an occlusive thrombosis of the porta or one of the principal branches~* Presence of a thrombosis of the sus-hepatic vein~* Active extra-hepatic malignant tumor~* Decompensated cardio-vascular disease~* Patient unwilling to participate to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transversus Abdominis Plane Block in Children Undergoing Ostomy Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* children undergoing revision or closure of ostomy~* American Society of Anesthesiologists Classification 1-3.~* age ≥ 3 months~Exclusion Criteria:~* children undergoing an additional surgical procedure (e.g. circumcision) at an anatomical location not covered by a one-sided/ unilateral TAP block, during the same anesthetic~* children in whom a TAP block is contraindicated, i.e. surgical scar or distorted anatomy at the site of injection~* postoperative admission to the intensive care unit~* children with a known allergy to bupivacaine~* children with a history of chronic abdominal pain~* use of opioid analgesics prior to surgery~* pregnancy~* impaired renal function~* impaired hepatic function~* known impaired cardiac function~* hypersensitivity to sodium metabisulfite

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Bupivacine-TAP block
- Control Group (Type: ACTIVE_COMPARATOR): Bupivacaine- wound infiltration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Forced Fluid Removal in High Risk Acute Kidney Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years of age~* Acute Kidney Injury defined according to the KDIGO criteria~* Renal Recovery Score ≤ 60%. (Calculated using www.renal-recovery-score.com)~* Fluid overload defined as a positive fluid balance ≥ 10% of ideal body weight.~* Able to undergo randomization within 12 hours of fulfilling other inclusion criteria~Exclusion Criteria:~* Known pre-hospitalization advanced chronic kidney disease. (eGFR \< 30 mL/minute/1.73 m2 or chronic RRT.)~* Severe hypoxic respiratory failure (use of invasive ventilation and FiO2 \> 80% and PEEP \> 10 cm H2O)~* Severe burn injury (≥ 10% TBSA)~* Severe hypo- or hyper- natremia (\< 120 or \> 155 mmol/l)~* Hepatic coma~* Mentally disabled undergoing forced treatment~* Pregnancy/breast feeding~* Lack of commitment for on-going life support including RRT~* Lack of informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Forced Fluid Removal (Type: EXPERIMENTAL): The experimental intervention is guided by a therapeutic goal of average negative fluid balance ≥ 1 ml/kg/h and safety variables indicating inadequate circulation (lactate ≥ 4, MAP \< 50 or mottling beyond the edge of kneecaps).~The effect of fluid removal is evaluated three times daily (06:00. 14:00 and 22:00), while the safety variables are evaluated continuously. Resuscitation is started if one or more signs of inadequate circulation is present.~The first choice for fluid removal is diuretic therapy with furosemide, which is continued for a minimum of 8 hours. If the therapeutic goal (negative fluid balance ≥ 1 ml/kg/h) is not achieved and/or maintained by furosemide alone, then fluid removal with continuous renal replacement therapy (CRRT) is initiated.
- Usual Care (Type: ACTIVE_COMPARATOR): Usual Care at the discretion of the treating clinicians, except for the initiation of renal replacement therapy (RRT).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Extend the Maximum Maintenance Flushing Interval for Ports With Distally Valved Catheters

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age ≥ 21 years~* Subject has an implanted Bard port with a distally-valved catheter~* Subject has maintenance port flushes with heparin/heparinized saline or normal saline~* Subject is post infusional cancer therapy (solid tumor or hematologic)~* Subject has signed a HIPAA Authorization to use and disclose PHI~Exclusion Criteria:~* Subject is having port maintenance flushes/locks with citrate.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: None): Maintenance flushes at days 1-28
- Group B (Type: None): Maintenance flushes at days 29-56
- Group C (Type: None): Maintenance flushes at days 57+

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI) at presentation for index PCI who have successfully completed \>1-year follow-up of RAPID MANAGE or TAILOR-PCI trials without having incurred an ischemic or bleeding outcome while on DAPT~* Patients with DAPT interruption after 1 year will be eligible, if within 3 years of index MI~Patients must also have 1 of the following atherothrombotic risk enrichment criteria:~* age ≥ 65 years~* diabetes~* 2nd prior MI (\> 1 year ago)~* multi-vessel coronary disease~* Creatinine Clearance \< 60mL/min~Exclusion Criteria:~Patients will be excluded from the study if they:~* refuse consent~* are \> 3 years post MI~* are deemed to require a P2Y12 inhibitor~* require oral anticoagulation~* have a history of stroke, transient ischemic attack (TIA) or intracranial bleed~* have had a recent GI bleed or major surgery~* have a life expectancy of \< 1 year~* have a platelet count \< 100,000/μl~* have a bleeding diathesis~* have hematocrit \< 30% or \> 52%~* are on dialysis or have severe liver disease~* are at risk for bradycardia

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Personalized Treatment Algorithm (Type: EXPERIMENTAL): A DAPT score using various patient demographics will be calculated:~If score under 2, patients will receive only aspirin 81 mg once daily~If DAPT score is ≥ 2~* A point-of-care bedside genetic test using a buccal swab will be conducted in order to determine medication regimen~* Those with a positive genetic test (presence of CYP2C19\*2 or CYP2C19\*3), will receive 60mg Ticagrelor twice daily~* Those with a negative genetic test (absence of CYP2C19\*2/\*3) will receive 75mg clopidogrel once daily
- Long-Term Ticagrelor (Type: ACTIVE_COMPARATOR): Patients will be given 60mg Ticagrelor twice daily with no aspirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Group-based or Individual Information About Disease and Treatment Plan

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Breast cancer patients that are candidates for adjuvant chemotherapy after surgery.~* Prostate cancer patients that are candidates for curative radiotherapy~* Signed informed consent~* Patient expected to be able to complete the planned treatment and the study procedures~* 18years or older~Exclusion Criteria:~-Patients not fulfilling inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group and Individual information (Type: EXPERIMENTAL): The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
- Individual information (Type: NO_INTERVENTION): Standard information about disease and treatment from doctor and nurse given at 2 occasions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transcutaneous Mechanical Nerve Stimulation in the Treatment of Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women suffering from stress incontinence OR Women suffering from urge incontinence /overactive bladder syndrome~* Ongoing anticholinergic treatment in the urge incontinence/overactive bladder syndrome group~* Patient capable of understanding protocol and performing treatment~Exclusion Criteria:~* On going pregnancy or breast feeding~* Treatment with anticholinergic medications in the stress incontinence group~* Treatment with diuretic drugs~* Acute illness (including infection, trauma and haematuria)~* Fibromyalgia~* Faecal incontinence~* Known neurological disease~* Bladder pain syndrome~* Genital prolaps \> stage 2 on the Pelvic Organ Prolapse Quantification System POP-Q~* Previous treatment with neuromodulation or Botox~* Previous pelvic floor surgery or radiation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TMNS treatment - Stress incontinence (Type: ACTIVE_COMPARATOR): Women with stress incontinence treated with active TMNS (vibration)
- No treatment - stress incontinence (Type: NO_INTERVENTION): Women with stress incontinence NOT treated with TMNS (vibration)
- TMNS treatment - Urge incontinence (Type: ACTIVE_COMPARATOR): Women with stress incontinence treated with TMNS (vibration)
- No treatment - urge incontinence (Type: NO_INTERVENTION): Women with urge incontinence NOT treated with TMNS (vibration)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study-mandated procedure.~* Patients with PAH who completed study AC-055-401~* Women of childbearing potential must:~* Have a negative urine pregnancy test at Visit 1 and agree to perform monthly serum pregnancy tests.~* Agree to use two methods of contraception from Visit 1 until 1 month after study drug discontinuation.~Exclusion Criteria:~* Patients who prematurely discontinued study drug in study AC-055-401~* Females who are lactating or pregnant (positive Visit 1 pregnancy test) or plan to become pregnant during the study~* Known hypersensitivity to macitentan or its excipients or drugs of the same class

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Macitentan (Type: EXPERIMENTAL): Macitentan tablet, dose of 10 mg, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Collar Immobilization Following a Posterior Cervical Laminectomy and Fusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* English Speaking~* Diagnosis of degenerative cervical spondylosis with symptomatic neurological compression (spinal cord and/or nerve root) requiring posterior decompression and instrumentation fusion~* Surgical construct to include instrumentation and fusion as proximal as C2 and as distal as T2~* Ability to provide written consent~* Ability to complete pre- and postoperative questionnaires~Exclusion Criteria:~* Diagnosis of malignancy, infection, fracture/dislocation of the cervical spine~* Posterior cervical constructs including the occiput or C1~* Previous cervical fusion to the occiput or C1~* Non-English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Collar (Type: ACTIVE_COMPARATOR): Hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
- No Collar (Type: EXPERIMENTAL): Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The VISION Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 12-85 years; of either gender.~* Confirmed PAH due to idiopathic pulmonary arterial hypertension (IPAH) or familial pulmonary arterial hypertension (FPAH).~* 6-minute walk distance (6-MWD) between 100-450 meters at screening.~* On a stable dose of sildenafil, with or without bosentan.~Exclusion Criteria:~* Any treatment for PAH with prostacyclins, prostacyclin analogues, endothelin-1 antagonists, or phosphodiesterase-5 (PDE-5) inhibitors other than sildenafil within the past 12 weeks.~* Pulmonary hypertension due to conditions other than those stated in inclusion criteria.~* Additional PAH medications added within the past 12 weeks.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- DB inhaled iloprost 6x/day (Type: EXPERIMENTAL): inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the double blind period
- DB inhaled iloprost 4x/day (Type: EXPERIMENTAL): Inhaled iloprost (5 μg) 4×/day plus inhaled placebo 2x/day plus sildenafil with or without bosentan during the double blind period
- DB inhaled placebo 6x/day (Type: PLACEBO_COMPARATOR): Inhaled placebo 6×/day plus sildenafil with or without bosentan during the double blind period
- OL inhaled iloprost 6x/day (Type: EXPERIMENTAL): Inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the Open-Label treatment period
- OL inhaled iloprost 4x/day (Type: EXPERIMENTAL): Inhaled iloprost (5 μg) 4 times per day (4×/day) plus sildenafil with or without bosentan during the Open-Label treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \<= 60 and undergoing allogeneic HSCT~* Life expectancy \> 8 weeks~* Scheduled for treatment with a conditioning regimen intended to be myeloablative~* Female subjects of child-bearing age must have a negative urine pregnancy test. Sexually active male and female subjects of reproductive age must be using a form of contraception considered effective and medically acceptable by the Investigator.~Exclusion Criteria:~* Cumulative lifetime exposure of \> 300 mg/M2 of anthracycline (expressed as doxorubicin equivalent dose) or receipt of anthracycline within 180 days prior to initiating conditioning for HSCT~* Active infection~* Prophylactic antibacterial antibiotics.~* Positive for HIV, HTLV-I, or HTLV-II~* Any prior stem cell transplant~* Prior history of CHF~* Cord blood is the source of a subject's transplanted cells.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Opebacan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues